Epstein Secrets

mith S. K.5, Olson V. A.5, Larone D.H.2, 6,&=bsp;Spitzer E.D.7, Barany F.2 and Golightly L.M.1, 2 1. Depa

sequencing. Earlier this year, I receiv=d the IFCC Award for Significant Contributions in Molecular Diagnostic=. I have been collaborating with Dr. Linnie Golightly of our Center for G=obal Health/Infectious Disease Division for the past decade, work=ng together closely to develop multiplexed PCR-LDR assays for

.4, Smith S. K.5, Olson V. A.5, Larone D.H.2, 6= Spitzer E.D.7, Barany F.2 and Golightly L.M.1, 2 1. Depa

sequencing. Earlier this year, I re=eived the IFCC Award for Significant Contributions in Molecular Diagn=stics. I have been collaborating with Dr. Linnie Golightly of our Center for =lobal Health/Infectious Disease Division for the past decade, wo=king together closely to develop multiplexed PCR-LDR assays for

mith S. K.5, Olson V. A.5, Larone D.H.2, 6,&=bsp;Spitzer E.D.7, Barany F.2 and Golightly L.M.1, 2 1. Depa

sequencing. Earlier this year, I receiv=d the IFCC Award for Significant Contributions in Molecular Diagnostic=. I have been collaborating with Dr. Linnie Golightly of our Center for G=obal Health/Infectious Disease Division for the past decade, work=ng together closely to develop multiplexed PCR-LDR assays for